Subgroup analysis of MRD-negative (10^–5) conversion rate from baseline to 12 months of maintenance treatment. ∗High risk is defined as positive for any of the following abnormalities: del(17p), t(14;16), or t(4;14). †Revised high-risk cytogenetics are defined as ≥1 of the following abnormalities: del(17p), t(4;14), t(14;16), t(14;20), and gain/amp(1q21). ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System.